Fabry disease treatment market value to reach $1.25b by 2024
6 August 2015 | By Victoria White
The global treatment market for Fabry disease will expand in value from $683 million in 2014 to approximately $1.25 billion by 2024...
List view / Grid view
News
Enrolment completes for Phase IIa trial of ATX-MS-1467
6 August 2015 | By Victoria White
Apitope today announced that its partner, Merck Serono, has completed patient enrolment for the Phase IIa study of ATX-MS-1467 (also known as M2736)...
CMA accuses Pfizer and Flynn Pharma of overcharging
6 August 2015 | By Victoria White
The CMA has accused Pfizer and Flynn Pharma of charging excessive and unfair prices in the UK for phenytoin sodium capsules, an anti-epilepsy drug...
NICE asks for more information on ovarian cancer drug olaparib
6 August 2015 | By Victoria White
NICE has opened a second consultation on preliminary draft guidance on olaparib for maintenance treatment of ovarian, fallopian tube and peritoneal cancer...
Phase III results for Vanda’s Hetlioz published in The Lancet
5 August 2015 | By Victoria White
Pivotal trial results from Phase III studies of Vanda Pharmaceuticals’ Hetlioz® (tasimelteon) have been published in The Lancet...
Lilly to end contract with UCSD for A4 Alzheimer’s study
5 August 2015 | By Victoria White
Lilly has notified UCSD of its intent to end its contract with the University for the management of the Alzheimer's disease A4 study...
Pharma sales surpassed $1 trillion in 2014
5 August 2015 | By Victoria White
The Intellectual Property and Science business of Thomson Reuters has released its 2015 CMR Factbook, pharma's leading resource of global R&D trends...
EC approves Pfizer’s pending acquisition of Hospira
5 August 2015 | By Victoria White
The ECs has approved Pfizer’s pending acquisition of Hospira - a transaction that will greatly expand Pfizer's sterile injectable pharmaceuticals portfolio...
EC grants Orphan Drug Designation to SGX301
4 August 2015 | By Victoria White
The EC has granted orphan drug designation to Solgenix’s synthetic hypericin (the active ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma...
Shire makes unsolicited bid to buy Baxalta
4 August 2015 | By Victoria White
Shire made a proposal to Baxalta on 10 July 2015 to combine the companies in an all-stock transaction worth approximately $30.6 billion...
Sanofi’s Toujeo now available in the UK
4 August 2015 | By Victoria White
Toujeo is now available in the UK, providing another option for adults with type 1 and type 2 diabetes mellitus to help manage their condition...
FDA approves first ever 3D printed drug product: Spritam
4 August 2015 | By Victoria White
The FDA has approved 3D printed drug Spritam for the treatment of of partial onset seizures, myoclonic seizures and generalised tonic-clonic seizures...
Pfizer and Synthon enter commercialisation agreement
4 August 2015 | By Victoria White
Pfizer and Synthon have entered into an agreement whereby Pfizer has acquired the exclusive commercialisation rights in the US to glatiramer acetate...
FDA accepts Mundipharma EDO’s IND for EDO-S101
3 August 2015 | By Victoria White
The FDA has accepted Mundipharma EDO’s IND for EDO-S101, a fusion molecule to treat relapsed/refractory haematologic malignancies and solid tumours...
Shire adds FST-100 to pipeline with Foresight acquisition
3 August 2015 | By Victoria White
Shire has acquired Foresight Biotherapeutics, gaining global rights to FST-100 - a therapy in development for the treatment of infectious conjunctivitis...
